Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472411 | 0.74 | GAA (0.49) | NOTUMHSD17B10ALDH1A1LMNAPOLB | |
| SCHEMBL12071484 | 0.72 | NOTUM (0.50) | NOTUMLMNAPOLBCASP3HSP90AB1 | |
| SCHEMBL472399 | 0.72 | NOTUM (0.45) | NOTUMALDH1A1LMNAPOLBNPC1 | |
| SCHEMBL9953638 | 0.72 | NOTUM (0.47) | NOTUMHSD17B10ALDH1A1LMNAPOLB | |
| SCHEMBL29719717 | 0.72 | NOTUM (0.53) | NOTUMPOLBCASP3HSD11B1 | |
| SCHEMBL12693194 | 0.71 | NOTUM (0.44) | NOTUMHSD17B10ALDH1A1LMNAPOLB | |
| SCHEMBL8021753 | 0.70 | IMPDH2 (0.39) | ALDH1A1NPC1RAB9AIMPDH2IMPDH1 | |
| SCHEMBL23451556 | 0.69 | NOTUM (1.00) | NOTUMALDH1A1LMNANPC1RAB9A | |
| SCHEMBL13393503 | 0.69 | IMPDH2 (0.38) | IMPDH2IMPDH1MAPK14 | |
| SCHEMBL30412729 | 0.69 | NOTUM (1.00) | NOTUMALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | NOTUM 3762/4885HSD17B10 3745/4885ALDH1A1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.